Posted by Michael Wonder on 02 Dec 2016
ICER's final report on targeted immunomodulators for plaque psoriasis offers guidance for policy and practice
2 December 2016 - Independent CEPAC votes on value and subsequent policy roundtable discussion suggest that drug prices after rebates align well with added value for patients, and therefore insurers should consider limiting or abolishing step therapy coverage policies
The Institute for Clinical and Economic Review (ICER) has released a final evidence report and meeting summary on the comparative clinical effectiveness and value of targeted immunomodulators for treatment of moderate to severe plaque psoriasis.
The Council voted that the evidence was not adequate to distinguish among the different IL-17A drugs, but several head-to-head studies have demonstrated that IL-17A agents, along with the IL-12/23 inhibitor ustekinumab, provide increased net health benefit over etanercept. A majority of the Council also voted that all FDA-approved drugs under review represent an intermediate or high long-term value for money. This assessment of value accounts for numerous factors, including net health benefit, cost, benefits or disadvantages of the treatment, and other contextual considerations.
